Bayer Aktiengesellschaft (FRA:BAYN)
Germany · Delayed Price · Currency is EUR 44.48
+0.43 (0.98%)
At close: Jan 30, 2026
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 9.66B EUR in the quarter ending September 30, 2025, a decrease of -3.09%. This brings the company's revenue in the last twelve months to 45.87B, down -1.87% year-over-year. In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B, down -2.16%.
Revenue (ttm)
45.87B
Revenue Growth
-1.87%
P/S Ratio
0.95
Revenue / Employee
518.25K
Employees
88,502
Market Cap
43.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mainova AG | 3.89B |
| Gelsenwasser AG | 3.36B |
| Paul Hartmann AG | 2.44B |
| Lechwerke AG | 1.06B |
| tonies SE | 510.38M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |
Bayer Aktiengesellschaft News
- 3 days ago - Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL' Campaign - Business Wire
- 3 days ago - Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar - Seeking Alpha
- 3 days ago - Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea 2mg - Wallstreet:Online
- 4 days ago - Bayer to build new canola research and development site in Winnipeg - CBC News
- 4 days ago - Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada - Business Wire
- 5 days ago - Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention - Business Wire
- 10 days ago - Bayer Announces FDA's Orphan Drug Designation For OpCT-001 To Treat Retinitis Pigmentosa - Nasdaq
- 12 days ago - Bayer Shares Jump as Supreme Court Agrees to Review Key Roundup Case - Nasdaq